Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ZIOPHARM Oncology Inc.    ZIOP

ZIOPHARM ONCOLOGY INC. (ZIOP)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsTweets
OFFRE

ZIOPHARM to Present at the Stifel 2017 Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/10/2017 | 10:06pm CEST

BOSTON, Nov. 10, 2017 (GLOBE NEWSWIRE) -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that David Mauney, M.D., CBO and interim COO, will present at the Stifel 2017 Healthcare Conference in New York on Tuesday, November 14, 2017 at 11:00 a.m. ET.

To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing innovative gene expression, control and cell technologies to deliver safe, effective and scalable cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. The Company's immuno-oncology programs, in collaboration with Intrexon Corporation (NYSE:XON) and the MD Anderson Cancer Center, include chimeric antigen receptor T cell (CAR-T) and other adoptive cell-based approaches that use non-viral gene transfer methods for broad scalability. The Company is advancing programs in multiple stages of development together with Intrexon Corporation's RheoSwitch Therapeutic System® (RTS®) technology, a switch to turn on and off, and precisely modulate, gene expression in order to improve therapeutic index. The Company's pipeline includes a number of cell-based therapeutics in both clinical and preclinical testing which are focused on hematologic and solid tumor malignancies.

Contact:
David Pitts
Argot Partners
212-600-1902
david@argotpartners.com


© GlobeNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ZIOPHARM ONCOLOGY INC.
09/18Palatin Technologies, Inc. - Immunotherapy Market Value Grows as the Treatmen..
AQ
09/06ZIOPHARM ONCOLOGY : Announces Scott Braunstein, M.D., Operating Partner at Aisli..
AQ
09/04CORRECTING and REPLACING -- Ziopharm Oncology Announces Scott Braunstein, M.D..
GL
09/04Ziopharm Oncology Announces Scott Braunstein, M.D., Operating Partner at Aisl..
GL
08/16ZIOPHARM ONCOLOGY : Reports Second Quarter 2018 Financial Results and Provides C..
AQ
08/10ZIOPHARM ONCOLOGY : Announces Changes to its Board of Directors
AQ
08/09ZIOPHARM : 2Q Earnings Snapshot
AQ
08/08ZIOPHARM ONCOLOGY INC : Results of Operations and Financial Condition, Financial..
AQ
08/08ZIOPHARM ONCOLOGY : Management's Discussion and Analysis of Financial Condition ..
AQ
08/08Ziopharm Oncology Reports Second Quarter 2018 Financial Results and Provides ..
GL
More news
News from SeekingAlpha
09/05Gene therapy players under pressure 
09/01Ziopharm Oncology Is An Attractive Buy For 2018 
08/16FDA and NIH to loosen oversight of gene therapy development 
08/15Investors shun healthcare stocks in broad market selloff 
08/14ONE YEAR LATER : Lessons Learned In CAR-T 
Financials ($)
Sales 2018 0,63 M
EBIT 2018 -53,1 M
Net income 2018 -68,3 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 677x
Capi. / Sales 2019 84,3x
Capitalization 427 M
Chart ZIOPHARM ONCOLOGY INC.
Duration : Period :
ZIOPHARM Oncology Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ZIOPHARM ONCOLOGY INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Average target price 4,25 $
Spread / Average Target 42%
EPS Revisions
Managers
NameTitle
Laurence James Neil Cooper Chief Executive Officer
David M. Mauney Chief Operating & Business Officer, Executive VP
Kevin G. Lafond Treasurer, Chief Accounting Officer & SVP-Finance
Francois Lebel Chief Medical Officer, EVP-Research & Development
Murray F. Brennan Lead Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
ZIOPHARM ONCOLOGY INC.-27.54%386
GILEAD SCIENCES2.83%94 348
VERTEX PHARMACEUTICALS17.31%44 927
REGENERON PHARMACEUTICALS2.80%41 024
NEUROCRINE BIOSCIENCES, INC.51.26%10 617
GENMAB1.51%10 236